A Synthetic Cannabinoid Rescued Memory Deficits in Alzheimer's Mice

Therapeutic WIN 55,212-2 treatment rescued recognition memory and spatial reference deficits. Preventative treatment rescued spatial learning and reference memory. The treatment did not affect anxiety-like behavior. WIN treatment reduced hippocampal microgliosis in preventatively treated mice and restored brain glucose metabolism in therapeutically treated mice. Both regimens increased locomotor activity.

Tg4-42 transgenic Alzheimer's mice received WIN 55,212-2 in two protocols: preventative (before symptoms) with prolonged washout, and therapeutic (during symptoms). Behavioral tests assessed memory, anxiety, and locomotion. Brain pathology assessed inflammation, amyloid-beta, neurogenesis, and glucose metabolism.

Despite recent anti-amyloid antibody approvals for Alzheimer's, there remains a critical need for accessible disease-modifying therapies. This study shows a synthetic cannabinoid can rescue memory and reduce inflammation in a mouse model without the anxiety side effects sometimes associated with cannabinoids.

The endocannabinoid system is increasingly recognized as a therapeutic target for neurodegenerative diseases. This study adds to growing preclinical evidence that cannabinoid receptor modulation can address multiple aspects of Alzheimer's pathology simultaneously, including memory, inflammation, and metabolism.

Tg4-42 model does not replicate all aspects of human Alzheimer's. Synthetic cannabinoid WIN 55,212-2 has different properties than plant-derived cannabinoids. Increased locomotor activity needs to be better understood. Animal memory tests have limited correspondence to human cognitive decline.